NCT03133221 · OUTCOME

Progression-free Survival at 1 and 2 Years After Autologous Stem Cell Transplantation.

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation · Source last updated 2025-06-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 1- and 2-year Progression-free survival

What was measured

1- and 2-year Progression-free survival; Progression-free survival is defined as time from the date of autologous stem cell transplantation to progression, relapse and death, whichever comes first.

Groups in this outcome

Oral Zydelig 150 mg BID

Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity. Zydelig: Zydelig given at 150mg continuously in 28-day cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Oral Zydelig 150 mg BID	17

Reported measurements

Source class 1

Progression-free survival

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Oral Zydelig 150 mg BID	13	Not reported	Not reported	Not reported	Not reported

1 year post transplant relapse

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Oral Zydelig 150 mg BID	1	Not reported	Not reported	Not reported	Not reported

2 year post transplant relapse

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Oral Zydelig 150 mg BID	3	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
13
title
Progression-free survival
measurements
group Id
OG000
value
1
title
1 year post transplant relapse
measurements
group Id
OG000
value
3
title
2 year post transplant relapse

denoms

counts
group Id
OG000
value
17
units
Participants

description

1- and 2-year Progression-free survival; Progression-free survival is defined as time from the date of autologous stem cell transplantation to progression, relapse and death, whichever comes first.

groups

description
Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity. Zydelig: Zydelig given at 150mg continuously in 28-day cycles
id
OG000
title
Oral Zydelig 150 mg BID

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

1- and 2-year Progression-free survival

title

Progression-free Survival at 1 and 2 Years After Autologous Stem Cell Transplantation.

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice